UniQure tumbles with latest data for Huntington’s gene therapy
Published . Updated .
Analysts guessed that investors wanted to see stronger durability results at a four-year check-in of the key trial supporting a potential approval of "AMT-130."
Directly affected
- HBANL HUNTINGTON
The reported development directly names HUNTINGTON in the headline; GA resolved that company to HBANL.
Indirectly affected
- GIEQ GOLDMAN SACHS ETF TR DATA ENHA
GA selected GIEQ as a RELATED security because its canonical security name directly matches this event's themes: data. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- RACK VANECK ETF TR VANECK DATA CENT
GA selected RACK as a RELATED security because its canonical security name directly matches this event's themes: data. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
Analysts guessed that investors wanted to see stronger durability results at a four-year check-in of the key trial supporting a potential approval of "AMT-130."
Source: BioPharma Dive
How far Huntington Bancshares (HBANL) has moved since 29 Sep 2026
Since the first closing price after “UniQure tumbles with latest data for Huntington’s gene therapy,” Huntington Bancshares (HBANL) is -1.46%. The S&P 500 fund (SPY) is +0.56% over the same days, a -2.02% difference versus the market.
Who gains and who loses around Huntington Bancshares (HBANL)
Companies tied to this story
- HBANL Huntington Bancshares
For “UniQure tumbles with latest data for Huntington’s gene therapy,” Huntington Bancshares (HBANL) is linked, with no stored direction, high confidence. Reason on file: The reported development directly names HUNTINGTON in the headline; GA resolved that company to HBANL
- GIEQ Goldman Sachs Etf Tr Data Enha
In “UniQure tumbles with latest data for Huntington’s gene therapy,” Goldman Sachs Etf Tr Data Enha (GIEQ) is linked, with no stored direction, medium confidence. Reason on file: GA selected GIEQ as a RELATED security because its canonical security name directly matches this event's themes: data. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- RACK Vaneck Etf Tr Vaneck Data Cent
Vaneck Etf Tr Vaneck Data Cent (RACK) is linked, with no stored direction, medium confidence in the 29 Sep 2026 story “UniQure tumbles with latest data for Huntington’s gene therapy.” Reason on file: GA selected RACK as a RELATED security because its canonical security name directly matches this event's themes: data. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Huntington Bancshares (HBANL)
“UniQure tumbles with latest data for Huntington’s gene therapy” (29 Sep 2026) reaches Huntington Bancshares (HBANL) through this story.
What ties Huntington Bancshares (HBANL) to the headline is this: The reported development directly names HUNTINGTON in the headline; GA resolved that company to HBANL
Goldman Sachs Etf Tr Data Enha (GIEQ) is here too. Its reason reads: GA selected GIEQ as a RELATED security because its canonical security name directly matches this event's themes: data. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Price levels for Huntington Bancshares (HBANL)
GIEQ traded between 41.01 and 42.36 across 6 sessions. The latest close on file is 41.10. HBANL traded between 24.57 and 25.11 across 11 sessions. The latest close on file is 24.64. RACK traded between 44.78 and 51.45 across 20 sessions. The latest close on file is 44.78.
A simple score for Huntington Bancshares (HBANL)
27 out of 100
“UniQure tumbles with latest data for Huntington’s gene therapy” scores 27 out of 100. The score uses 1 sources, and 3 linked companies.